Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces positive new ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal ...
A study reveals specialized base barrier cells in the choroid plexus that seal off the brain and cerebrospinal fluid. During ...
Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, ...
Central Square Foundation (CSF) hosted the EdTech and AI Convening - Education Dialogues, a satellite event of the India AI ...
Metabolomics-Derived Pathway Scores Outperform Inflammatory Protein Markers-Delivering Risk Prediction Where Proteomics Falls ShortMORRISVILLE, N.C., Feb. 17, 2026 /PRNewswire/ -- Metabolon ...
The central question is no longer whether we can innovate, but whether innovation can truly reach patients in time.
Kyntra Bio Inc. KYNB, formerly Fibrogen, shares fluctuated in Tuesday’s premarket session as the company announced data from a Phase 1b/2 study of FG-3246 in combination with enzalutamide for treating ...
FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, ...
News-Medical.Net on MSN
Study identifies PPP2R5C blood marker that may detect Alzheimer’s disease earlier
By Tarun Sai Lomte Researchers report that declining PPP2R5C levels in blood may signal early Alzheimer’s pathology, offering ...
A new study reveals a hidden brain defense: base barrier cells. These cells form a molecular seal in the choroid plexus, acting as a gatekeeper against systemic inflammation and potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results